The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3774-3781

  Defronzo, Ralph A ^a,b   Tripathy, Devjit ^a,b   Abdul Ghani, Muhammad ^a   Musi, Nicolas ^a   Gastaldelli, Amalia ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DEGRADATION; DISPOSITION INDEX; DRUG DOSE INCREASE; FEMALE; GLUCONEOGENESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MATSUDA INDEX; MIDDLE AGED; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VALIDITY; WAIST CIRCUMFERENCE; DRUG EFFECTS; DRUG MONITORING; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; METABOLISM; PROCEDURES; SECRETION (PROCESS);

BLOOD GLUCOSE; BODY MASS INDEX; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES;

EID: 84907637368     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1515     Document Type: Article

References (26)

1. Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia. 2004;47:943-956.
2. Mari A, Tura A, Natali A, et al. Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia. 2010;53:749-756.
3. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, De-Fronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90:493-500.
4. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, De Fronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol Endocrinol Metab. 1983;244:E517-E527.
5. Jones CN, Pei D, Staris P, et al. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab. 1997;82:1834-1838.
6. Flier JS, Minaker KL, Landsberg L, Young JB, Pallotta J, Rowe JW. Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin. Diabetes. 1982;31:132-135.
7. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992;41:368-377.
8. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981;68:1456-1467.
9. Kahn SE. The importanceof beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058.
10. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity. 2008;16:1901-1907.
11. De Fronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115.
12. De Fronzo RA, Banerji M, Bray GA, et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009;9:17.
13. Defronzo RA, Tripathy D, Schwenke DC, et al. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013;62:3920-3926.
14. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
15. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24:539-548.
16. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, De-Fronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55:1430-1435.
17. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, De Fronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004;47:31-39.
18. Rossetti L, Giaccari A, De Fronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630.
19. Valera Mora ME, Scarfone A, Calvani M, Greco AV, Mingrone G. Insulin clearance in obesity. J Am Coll Nutr. 2003;22:487-493.
20. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000;106:329-333.
21. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52:2461-2474.
22. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, De Fronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord. 2004;28:783-789
23. Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, De Fronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37:1025-1035.
24. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-2791.
25. Bajaj M, Baig R, Suraamornkul S, et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:1916-1923.
26. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, De-Fronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292:E871-E883.